Table 3.
Joint-effect analysis of DUXAP8 and RNF2 for overall survival
| Group | DUXAP8 expression | RNF2 | Overall survival | |||||
|---|---|---|---|---|---|---|---|---|
| Events/total | MST (Days) | Crude HR (95%CI) | Crude P value | Adjusted HR (95%CI) | Adjusted P valueɸ | |||
| A | Low | Low | 39/120 | 2116 | Ref. | <0.0001 | Ref. | 0.001 |
| B | Low | High | 35/130 | 2542 | 1.001 (0.633-1.584) | 0.995 | 1.030 (0.626-1.694) | 0.908 |
| High | Low | |||||||
| C | High | High | 56/120 | 837 | 2.268 (1.498-3.433) | <0.001 | 2.184 (1.364-3.497) | 0.001 |
Note: ɸ: P values were adjusted for radical resection, tumor stage and HBV infection; Bold indicates significant P values, NA: not available; MST: median survival time; HR: hazard ratio; 95%CI: 95% confidence interval.